跳至主要内容
临床试验/IRCT20090117001556N143
IRCT20090117001556N143尚未招募2 期

Pentoxifylline as an adjuvant therapy in the treatment of negative symptoms of Schizophrenia: A randomized double blind and placebo controlled clinical trial

Tehran University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 60 years(—)
性别
All

入选标准

  • Diagnosis of schizophrenia based on DSM-5
  • Age between 18-60
  • At least 2 years have been passed since the diagnosis
  • Have been stable with risperidone treatment for at least 2 months
  • <14 HDRS score
  • >15 PANSS score for negative symptoms

排除标准

  • Head trauma
  • History of shock therapy during the last three months
  • Neurosurgery
  • Diagnosis of acute or chronic systemic disease
  • History of drug allergy to risperidone or pentoxifylline
  • Alcohol or drug addiction in the last 6 months
  • Suicidal ideation
  • Pregnancy or lactation
  • IQ less than 70 based on the diagnosis of a psychiatrist.

研究者

相似试验